Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.43 |
| ▸ | F3 | P13726 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452339 | 0.85 | F2 (0.48) | NAMPTCYP2C9DAOF2HDAC1 | |
| SCHEMBL30765591 | 0.83 | NAMPT (0.48) | NAMPTCYP2C9DAOF2HDAC1 | |
| SCHEMBL23461311 | 0.81 | F2 (0.52) | NAMPTCYP2C9DAOF2HDAC1 | |
| SCHEMBL23461309 | 0.81 | F2 (0.52) | NAMPTCYP2C9DAOF2HDAC1 | |
| SCHEMBL11856052 | 0.80 | LOXL2 (0.56) | HDAC1HDAC3HDAC2 | |
| SCHEMBL23478663 | 0.77 | SMN1; SMN2 (0.48) | NAMPTCYP2C9F2CACNA1HSMN1; SMN2 | |
| SCHEMBL30632885 | 0.77 | SMN1; SMN2 (0.48) | NAMPTCYP2C9F2CACNA1HSMN1; SMN2 | |
| SCHEMBL29202481 | 0.76 | F2 (0.49) | NAMPTCYP2C9DAOF2HDAC1 | |
| SCHEMBL29202484 | 0.76 | F2 (0.49) | NAMPTCYP2C9DAOF2HDAC1 | |
| SCHEMBL6066464 | 0.76 | LOXL2 (0.56) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |